SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. Details of the company's participation are as follows: Truist Healthcare ConferenceDetails: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: November 7, 2 ...

The U.S. presidential election will be held on November 5, 2024, but there’s another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Society will hold its annual meeting, ObesityWeek 2024. Viking Therapeutics Inc. NASDAQ: VKTX will be a key presenter. Viking Therapeutics TodayVKTXViking Therapeutics$71.75 -1.60 (-2.18%) 52-Week Range$9.32▼$99.41Price Target$108.60Add to WatchlistViking will provide updates on its lead candidate's progress, VK2735 ...

It might not be too late to get in on the party. If there were a "revelation of the year" award for each industry on the stock market, Viking Therapeutics (VKTX -2.18%) would be a leading contender for the biotech sector. The mid-cap drugmaker impressed investors with promising clinical progress in the hottest therapeutic area in the industry: weight loss. Viking has been rewarded. The company's shares are up substantially year to date. However, recent developments, some of which the company revealed in its ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end October, consider joining Out Fox The Street . Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and dir ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been over five months since my previous Viking Therapeutics (NASDAQ: VKTX ) article , where I laid out a case for Viking Therapeutics as a prime acquisition target thanks to their impressive pipeline targeting obesity, NASH, X-ALD, and sarcopenia. ...

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.Viking Therapeutics (VKTX 21.25%) was an outlier on the stock exchange Thursday, in the best way possible. Within its latest earnings release, the biotech had some encouraging news to report, and investors rewarded the company by sending its share price up by more than 21%. With that giant gain, the stock absolutely crushed the S&P 500 index, which only inched up by 0.2%.Third-quarter resu ...

Viking Therapeutics (VKTX) reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share in the year-ago quarter.Currently, Viking Therapeutics does not have any approved product in its portfolio. Hence, it is yet to generate revenues.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.More on VKTX’s Q3 EarningsResearch and development expenses totaled $22.8 million, up 24% ...

Financial Data and Key Metrics - Research and development expenses for Q3 2024 were $22.8 million, up from $18.4 million in Q3 2023, driven by increased manufacturing costs, stock-based compensation, and salaries [7] - General and administrative expenses for Q3 2024 were $13.8 million, up from $8.9 million in Q3 2023, primarily due to stock-based compensation, legal services, and third-party consulting [8] - Net loss for Q3 2024 was $24.9 million ($0.22 per share), compared to a net loss of $22.5 million ($0.23 per share) in Q3 2023 [8] - Cash, cash equivalents, and short-term investments stood at $930 million as of September 30, 2024, up from $362 million at the end of 2023 [11] Business Line Data and Key Metrics - VK2735 (obesity treatment): Phase 2 VENTURE trial showed up to 14.7% weight reduction after 13 weeks, with no plateau observed [13] - VK2809 (NASH and fibrosis treatment): Phase 2b VOYAGE trial achieved primary and secondary endpoints, with 63-75% NASH resolution rates and 44-57% fibrosis improvement rates [20] - VK0214 (X-ALD treatment): Phase 1b trial demonstrated safety and significant reductions in plasma levels of very long-chain fatty acids [24] - Oral VK2735: Phase 1 trial showed up to 5.3% weight reduction after 28 days, with dose escalation up to 100 mg completed [18][40] Market Data and Key Metrics - The obesity drug market is projected to exceed $40 billion in revenue, with injectable formulations expected to dominate (80% share) over oral formulations (20% share) [46] - The company is exploring monthly dosing for VK2735, which could serve as a maintenance regimen for weight management [32][65] Company Strategy and Industry Competition - The company plans to advance VK2735 into Phase 3 development for obesity, with an end-of-Phase 2 meeting scheduled with the FDA [15] - A new amylin agonist program is under development, with potential for combination therapy with VK2735 to enhance efficacy [26][36] - The company is evaluating partnerships for the NASH program (VK2809) and is in discussions with global peptide suppliers for long-term manufacturing capacity [42][56] Management Commentary on Operating Environment and Future Outlook - Management highlighted the strong balance sheet, which provides sufficient runway to execute key clinical milestones [25] - The company is optimistic about the potential of its pipeline, particularly the dual agonist VK2735 and the amylin agonist program, which could offer best-in-class efficacy [36][62] Other Important Information - The company submitted abstracts for the VENTURE and oral VK2735 Phase 1 trials for presentation at the ObesityWeek conference in November [14][18] - Results from the VOYAGE study will be presented at the AASLD Annual Meeting in November [22] Q&A Session Summary Question: End-of-Phase 2 meeting for VK2735 - The company plans to discuss trial design, dosing, and size with the FDA, aiming to finalize the Phase 3 protocol [29] Question: Monthly dosing for VK2735 - PK data supports monthly dosing, but it will likely be tested in a standalone study rather than included in the Phase 3 trial [32] Question: Oral VK2735 dosing regimens - The company is exploring additional dosing regimens and will disclose the Phase 2 study design closer to initiation [33] Question: Manufacturing capacity and infrastructure - The company is expanding its internal team and relying on external vendors to support upcoming Phase 3 trials [33] Question: Active control arm in Phase 3 - The Phase 3 study will be placebo-controlled, with potential for active comparator studies in the future [35] Question: Amylin agonist development strategy - The company plans to test the amylin agonist in combination with VK2735, with clinical trials expected to begin in 2025 [36] Question: Auto-injector for VK2735 Phase 3 - The company plans to use an auto-injector in the Phase 3 trial, with discussions ongoing to secure materials [50] Question: X-ALD program next steps - The next step for VK0214 is likely a registrational study, potentially focusing on functional or quality-of-life endpoints [52] Question: Maintenance dosing for VK2735 - Monthly dosing is viewed as a maintenance regimen, with potential to transition patients from weekly to monthly dosing [65] Question: Amylin and calcitonin receptor agonism - The company is targeting a balanced mechanism for its amylin agonist, as compounds with balanced receptor activity show better weight loss profiles [68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...

Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 • Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 • Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLD • Positive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductio ...